Evidence map›Paper›PMID 35438757›Full record

ArticleJAMA network open2022

Assessment of Community-Level Vulnerability and Access to Medications for Opioid Use Disorder.

Paul J Joudrey, Marynia Kolak, Qinyun Lin, Susan Paykin, Vidal Anguiano, Emily A Wang

Abstract read
In one paragraph

Article in JAMA network open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Mobile addiction treatment units: a narrative review.Addiction science & clinical practice · 2025
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Article
  18. Delivering MOUD to the Underserved: How Can Pharmacies Really Help?Journal of studies on alcohol and drugs · 2024
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Paul J JoudreyProgram in Addiction Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
Marynia KolakHealthy Regions & Policies Lab, Center for Spatial Data Science, University of Chicago, Chicago, Illinois.
Qinyun LinHealthy Regions & Policies Lab, Center for Spatial Data Science, University of Chicago, Chicago, Illinois.
Susan PaykinHealthy Regions & Policies Lab, Center for Spatial Data Science, University of Chicago, Chicago, Illinois.
Vidal AnguianoHealthy Regions & Policies Lab, Center for Spatial Data Science, University of Chicago, Chicago, Illinois.
Emily A WangProgram in Addiction Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.

Funding

Survey CoreU2CDA050098 · NIDA · UNIVERSITY OF CHICAGO · PI POLLACK, HAROLD ALEXANDER, SCHNEIDER, JOHN · 2019 to 2019
$17.2M
Yale Drug use, Addiction and HIV Research Scholars (DAHRS)K12DA033312 · NIDA · YALE UNIVERSITY · PI Gail D'Onofrio, Patrick O'Connor · 2013 to 2026
$7.2M
NIDA NIH HHS K12 DA033312NIDA NIH HHS L30 DA052056NIDA NIH HHS U2C DA050098
6 · The paper itself

Abstract

Importance: Given that COVID-19 and recent natural disasters exacerbated the shortage of medication for opioid use disorder (MOUD) services and were associated with increased opioid overdose mortality, it is important to examine how a community's ability to respond to natural disasters and infectious disease outbreaks is associated with MOUD access. Objective: To examine the association of community vulnerability to disasters and pandemics with geographic access to each of the 3 MOUDs and whether this association differs by urban, suburban, or rural classification. Design, Setting, and Participants: This cross-sectional study of zip code tabulation areas (ZCTAs) in the continental United States excluding Washington, DC, conducted a geospatial analysis of 2020 treatment location data. Exposures: Social vulnerability index (US Centers for Disease Control and Prevention measure of vulnerability to disasters or pandemics). Main Outcomes and Measures: Drive time in minutes from the population-weighted center of the ZCTA to the ZCTA of the nearest treatment location for each treatment type (buprenorphine, methadone, and extended-release naltrexone). Results: Among 32 604 ZCTAs within the continental US, 170 within Washington, DC, and 20 without an urban-rural classification were excluded, resulting in a final sample of 32 434 ZCTAs. Greater social vulnerability was correlated with longer drive times for methadone (correlation, 0.10; 95% CI, 0.09 to 0.11), but it was not correlated with access to other MOUDs. Among rural ZCTAs, increasing social vulnerability was correlated with shorter drive times to buprenorphine (correlation, -0.10; 95% CI, -0.12 to -0.08) but vulnerability was not correlated with other measures of access. Among suburban ZCTAs, greater vulnerability was correlated with both longer drive times to methadone (correlation, 0.22; 95% CI, 0.20 to 0.24) and extended-release naltrexone (correlation, 0.15; 95% CI, 0.13 to 0.17). Conclusions and Relevance: In this study, communities with greater vulnerability did not have greater geographic access to MOUD, and the mismatch between vulnerability and medication access was greatest in suburban communities. Rural communities had poor geographic access regardless of vulnerability status. Future disaster preparedness planning should match the location of services to communities with greater vulnerability to prevent inequities in overdose deaths.

Indexed as

BuprenorphineCOVID-19 Drug TreatmentOpioid-Related DisordersAnalgesics, OpioidCross-Sectional StudiesHealth Services AccessibilityHumansMethadoneNaltrexoneOpiate Substitution TreatmentUnited StatesAnalgesics, OpioidBuprenorphineMethadoneNaltrexone

Identifiers

PMID35438757
PMCPMC9020217

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.